Table 1

Name	Nanocarrier	Clinical Status	Compound	References
DaunoXome	Liposome	Approved	Daunorubicin	50, 56
Doxil/Caelyx	Liposome	Approved	Doxorubicin	2, 50, 56
CPX-1	Liposome	P1	Irinotecan	4
LE-SN38	Liposome	P2	SN-38	31
MCC465	Ab- liposome	P1	Doxorubicin	38
NK911	Micelle	P1	Doxorubicin	27, 56
SP1049C	Micelle	P3	Doxorubicin	9, 27, 53
NK105	Micelle	P2	Paclitaxel	24
NC-6004	Micelle	P1/2	Cisplatin	57
Zoladex*	Polymer rods	Approved	Goserelin acetate	12
Lupron Depot*	Polymer microspheres	Approved	Leuprolide acetate	1, 12
Oncaspar	PEG	Approved	L-Asparaginase	11
PEG intron	PEG	Approved	α-Interferon	7
Zinostatin	Polymer	Approved	SMANCS**	42
PK1	HPMA copolymer	P2/3	Doxorubicin	48
Abraxane	Albumin	Approved	Paclitaxel	39
Ontak	IL2 Fusion Protein	Approved	Diptheria toxin	15, 16
Zevalin	Anti-CD20	Approved	Yttrium-90/Indium-111	20
Bexxar	Anti-CD20	Approved	Iodine-131	20

*Polymers composed of polylactide-co-glycolide. **Styrene maleic anhydride neocarzinostatin.

Table 1: Examples of nanocarrier-based chemotherapeutics that are either clinically approved, or in various stages of clinical trials for cancer treatment.